智通财经APP获悉，九源基因(02566)尾盘涨近24%，截至发稿，涨23.72%，报15.28港元，成交额4121.5万港元。
消息面上，九源基因拟于8月18日(下周一)举行董事会会议以审批中期业绩。值得关注的是，由于手握国内潜在首款司美格鲁肽生物类似药，代谢一直是九源基因最为外界所关注的领域。此前，在3月27日的业绩交流会上，九源基因相关负责人提到，减重适应证2026年上半年报产(即提交药品上市申请)。对于司美格鲁肽的市场布局和渠道规划，将强化院内市场先发优势，通过药店网络下沉扩大可及性，联合电商平台战略合作，加速品牌建设与用户触达。
此外，九源基因还将司美格鲁肽的海外权益授权给了其他国内药企：与科兴生物签署了司美格鲁肽在拉美主要国家的市场独家许可合作协议；与复星医药签署了产品许可协议关键条款，给予复星医药司美格鲁肽在内的多款产品在中东和北非、撒哈拉以南非洲全部国家及部分东盟国家的独家临床开发、注册和商业化权利。预计2025年内向巴西、沙特递交司美格鲁肽的新药申请。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.